ChromaDex Announces Retail Distribution of Tru Niagen® in Walmart Stores Across the United States
March 10 2021 - 6:34AM
Business Wire
Industry-leading NAD+ booster and healthy aging nutrient Tru
Niagen® will be available in 3,000 Walmart stores across the U.S.
beginning in June 2021
ChromaDex Corp. (NASDAQ:CDXC) announced today its flagship
consumer product and industry-leading NAD+ booster Tru Niagen® will
be available in 3,000 Walmart retail stores across the United
States beginning June 2021. ChromaDex will introduce Tru Niagen® in
two packaging options for Walmart customers, which will have
distinct serving sizes and price points. In addition to in-store
availability, these two options will be available online with
same-day delivery and in-store pickup options for select
locations.
“We believe Tru Niagen® is one of the most important new dietary
supplements to emerge in many years,” says ChromaDex CEO Rob Fried.
“We are grateful to Walmart in assisting in our quest to help as
many people as possible to Age Better®.”
Tru Niagen® helps users Age Better® by safely and effectively
increasing NAD+ (nicotinamide adenine dinucleotide) supporting the
trillions of cells in the body. NAD+ levels decline with age as
well as physiological stressors including stress on the immune
system, alcohol consumption, over-exercising, and lack of healthy
sleep cycles. Niagen® (patented nicotinamide riboside) increases
NAD+ levels safely and efficaciously, as demonstrated in nine
published human trials. Niagen® has received regulatory acceptance
by the world’s four leading regulatory bodies: the U.S. FDA, Health
Canada, the European Commission, and the Therapeutic Goods
Administration (TGA) of Australia. Scientifically superior to
competing NAD+ precursors such as NMN (nicotinamide
mononucleotide), Niagen® is supported by a vast amount of safety
and efficacy data in humans.
For additional information on the science supporting Tru
Niagen®, please visit www.truniagen.com.
For additional information about ChromaDex, please visit
www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex delivers Niagen® as the sole active
ingredient in its consumer product Tru Niagen® available at
www.truniagen.com and through partnerships with global retailers
and distributors. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as "expects,"
"anticipates," "intends," "estimates," "plans," "potential,"
"possible," "probable," "believes," "seeks," "may," "will,"
"should," "could" or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2019 as amended, ChromaDex's
Quarterly Reports on Form 10-Q and other filings submitted by
ChromaDex to the SEC, copies of which may be obtained from the
SEC's website at www.sec.gov. Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date hereof, and actual results may differ
materially from those suggested by these forward-looking
statements. All forward-looking statements are qualified in their
entirety by this cautionary statement and ChromaDex undertakes no
obligation to revise or update this release to reflect events or
circumstances after the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210310005161/en/
ChromaDex Media Contact: Alex Worsham, Vice President of
Global Marketing & Communications 310-388-6706 ext. 689
alexw@chromadex.com ChromaDex Investor Relations Contact:
Brianna Gerber, Vice President of FP&A and Investor Relations
949-419-0288 ext. 127 briannag@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Aug 2024 to Sep 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Sep 2023 to Sep 2024